CD32a (131R) 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| GRANITE | GRANITE-001; GRT-C901/GRT-R902 | Phase 3 Clinical | Bristol-Myers Squibb Company, Gritstone Bio Inc | Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | 詳細 |
| 89Zr-Df-crefmirlimab | IAB-22-M2C | Phase 3 Clinical | Imaginab Inc | Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Multiple Sclerosis; Lymphoma; Leukoencephalopathy, Progressive Multifocal; Carcinoma, Non-Small-Cell Lung; Melanoma | 詳細 |
| RB-0003 | RB-0003; BNT-111 | Phase 2 Clinical | Biontech Se, Tron | Melanoma | 詳細 |
| GEN-009 | GEN-009 | Phase 2 Clinical | Genocea Biosciences Inc | Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | 詳細 |
| VE-800 | VE-800 | Phase 2 Clinical | Vedanta Biosciences Inc | Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Adenocarcinoma; Melanoma; Neoplasm Metastasis | 詳細 |
| EBViNT Cell (Eutilex) | Phase 2 Clinical | Eutilex | Lymphoma, Extranodal NK-T-Cell | 詳細 | |
| ZED88082A | ZED88082A | Phase 2 Clinical | Umcg The University Medical Center Groningen | Neoplasms; Neoplasm Metastasis | 詳細 |
| NY-ESO-1-specific autologous CD8+ T-cell therapy (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Liposarcoma; Sarcoma, Synovial; Sarcoma | 詳細 | |
| Tcrx T cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Esophageal Neoplasms; Stomach Neoplasms | 詳細 | |
| SCRI-E2CAR_EGFRtv1 | SCRI-E2CAR_EGFRtv1 | Phase 1 Clinical | Umoja BioPharma Inc | Osteosarcoma | 詳細 |
| 68-Ga-NODAGA-SNA-006 | SNA-006; 68-Ga-NODAGA-SNA-006 | Phase 1 Clinical | Smartnuclide Biopharma | Solid tumours | 詳細 |